Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Authors: Suga, J Marie | Annals Of Oncology : Official Journal Of The European Society For Medical Oncology | October 1, 2023 | PubMed abstract

Explore all publications

Back To Top